DURECT
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs
DURECT
Industry:
Biotechnology Health Diagnostics Pharmaceutical
Founded:
1998-01-01
Address:
Cupertino, California, United States
Country:
United States
Website Url:
http://www.durect.com
Total Employee:
51+
Status:
Active
Contact:
4088651406
Total Funding:
62.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Bluebird Bio
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2001-04-30 | Southern Biosystems | Southern Biosystems acquired by Durect | N/A |
| 1999-10-06 | IntraEAR, Inc. | IntraEAR, Inc. acquired by Durect | N/A |
Investors List
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Equity - Durect
Official Site Inspections
http://www.durect.com Semrush global rank: 4.25 M Semrush visits lastest month: 2.75 K
- Host name: durect.tempurl.host
- IP address: 45.77.184.238
- Location: San Jose United States
- Latitude: 37.3387
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95113
More informations about "Durect"
About Us | DURECT
About DURECT Our Purpose We’re advancing a novel therapeutic approach by harnessing the power of epigenetic modulation. We believe modulating the …See details»
DURECT | Unlocking the potential of epigenetic …
3 days ago DURECT harnesses epigenetic modulation to potentially treat serious and life-threatening conditions, including acute organ injury and …See details»
DURECT Corporation: Shareholders Board Members Managers and …
2 days ago DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic …See details»
Board of Directors | DURECT
Investors Overview Stock Information FAQs SEC Filings Press Releases Information RequestSee details»
Investors - DURECT
Durect is a biopharmaceutical company that leverages novel epigenetic regulation therapeutics for acute and chronic organ injury.See details»
Durect Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Durect has 5 employees at their 1 location and $2.03 m in annual revenue in FY 2024. See insights on Durect including office locations, competitors, revenue, financials, …See details»
Durect Corporation - VentureRadar
"DURECT is committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic …See details»
Bausch Health to Acquire DURECT Corporation, Strengthening …
2 days ago DURECT’s lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option …See details»
Bausch Health to Acquire DURECT Corporation, Strengthening …
3 days ago About DURECT Corporation DURECT Corporation (Nasdaq: DRRX) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target …See details»
DURECT - 2025 Company Profile & Team - Tracxn
Jul 4, 2025 DURECT is a public company based in Cupertino (United States), founded in 1998 by James E. Brown. It operates as a Developer of therapeutics for chronic diseases and pain. …See details»
DURECT Corporation Company Profile | Cupertino, CA
Find company research, competitor information, contact details & financial data for DURECT Corporation of Cupertino, CA. Get the latest business insights from Dun & Bradstreet.See details»
Durect - Crunchbase Company Profile & Funding
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage developmentSee details»
Bausch Health Acquires DURECT Corporation in Deal Worth up to …
1 day ago Strategic Acquisition: Bausch Health will acquire DURECT Corporation for $63 million upfront, with potential milestone payments of up to $350 million, expanding its late-stage liver …See details»
News - DURECT
March 19, 2025 DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference February 4, 2025 DURECT Corporation Announces Publication of …See details»
Bausch Health to Acquire DURECT Corporation, Strengthening
2 days ago Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver DiseaseSee details»
Bausch Health to Acquire DURECT Corporation ... - Morningstar
3 days ago DURECT Corporation (Nasdaq: DRRX) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation …See details»
Durect - News & Analysis - Crunchbase
May 13, 2025 DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage developmentSee details»
Bausch Health to Acquire DURECT Corporation, Strengthening …
2 days ago DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option …See details»
DURECT Corp. - Drug pipelines, Patents, Clinical trials - Synapse
DURECT is a specialized pharmaceutical corporation that focuses on creating cutting-edge medications for the treatment of pain and persistent illnesses. DURECT's exclusive oral, …See details»
Durect - Financial Details - Crunchbase
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage developmentSee details»